By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths - 2New dinosaur tracks in Italy illustrate herds moving in unison
- 3The most effective method to Pick the Right Material Organization: Fundamental Tips
- 4Father and son spending Christmas together after health scares
- 5Christmas 2025 skywatching guide: What you can see in the night sky on Dec. 25
- Strengthening through Wellness: Individual Preparation Achievement
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Famous Rough terrain Vehicles for 2024
- This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Pick Your #1 game to observe
- Vote In favor of Your Favored Web-based Visual depiction Administration
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- ByHeart infant formula recall tied to botulism outbreak puts parents on edge
